Safety, Efficacy and Patient Acceptability of the Contraceptive and Non-Contraceptive Uses of the LNG-IUS
暂无分享,去创建一个
[1] A. Lethaby,et al. Surgery versus medical therapy for heavy menstrual bleeding. , 2016, The Cochrane database of systematic reviews.
[2] J. Trussell. Medical eligibility criteria for contraceptive use , 2011 .
[3] D. Creedon,et al. Term pregnancy with intraperitoneal levonorgestrel intrauterine system: a case report and review of the literature. , 2009, Contraception.
[4] D. Lu,et al. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. , 2009, Contraception.
[5] C. Mangioni,et al. Fertility‐sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single‐institution experience of 21 cases , 2009, BJOG : an international journal of obstetrics and gynaecology.
[6] A. Ørbo,et al. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. , 2008, Gynecologic oncology.
[7] T. J. Clark,et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study. , 2008, European journal of obstetrics, gynecology, and reproductive biology.
[8] L. Dennis,et al. Meta-analysis of intrauterine device use and risk of endometrial cancer. , 2008, Annals of epidemiology.
[9] J. Jensen,et al. Subject and clinician experience with the levonorgestrel-releasing intrauterine system. , 2008, Contraception.
[10] O. Stephansson,et al. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial. , 2007, Human reproduction.
[11] L. Bahamondes,et al. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. , 2007, Contraception.
[12] J. Guest,et al. Cost-utility of levonorgestrel intrauterine system compared with hysterectomy and second generation endometrial ablative techniques in managing patients with menorrhagia in the UK , 2007, Current medical research and opinion.
[13] A. Kaunitz. Progestin-releasing intrauterine systems and leiomyoma. , 2007, Contraception.
[14] P. Castaño. Use of intrauterine devices and systems by HIV-infected women. , 2007, Contraception.
[15] E. Espey,et al. Intrauterine contraception: the pendulum swings back. , 2007, Obstetrics and gynecology clinics of North America.
[16] M. Khamashta,et al. Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil) , 2006, Lupus.
[17] J. Jensen,et al. A US multicenter open-label trial with the levonorgestrel-releasing intrauterine system clinical and device-related experience , 2006 .
[18] Pai-Lien Chen,et al. Pain from copper intrauterine device insertion: randomized trial of prophylactic ibuprofen. , 2006, American journal of obstetrics and gynecology.
[19] A. Ørbo,et al. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. , 2006, Gynecologic oncology.
[20] C. Farquhar,et al. A randomised trial comparing the levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding , 2006, BJOG : an international journal of obstetrics and gynaecology.
[21] R. Salem. New attention to the IUD: expanding women's contraceptive options to meet their needs. , 2006, Population reports. Series B, Intrauterine devices.
[22] M. Koskenvuo,et al. Use of the Levonorgestrel-Releasing Intrauterine System and Breast Cancer , 2005, Obstetrics and gynecology.
[23] D. Barlow,et al. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. , 2005, Human reproduction.
[24] R. Ferriani,et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. , 2005, Human reproduction.
[25] F. Lockhat,et al. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. , 2005, Human reproduction.
[26] R. Woolas,et al. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. , 2005, Gynecologic oncology.
[27] F. Lockhat,et al. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up , 2005 .
[28] S. Soysal,et al. The Efficacy of Levonorgestrel-Releasing Intrauterine Device in Selected Cases of Myoma-Related Menorrhagia: A Prospective Controlled Trial , 2005, Gynecologic and Obstetric Investigation.
[29] S. Deitcher,et al. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. , 2004, Archives of internal medicine.
[30] J. Schlesselman,et al. Safety concerns and health benefits associated with oral contraception. , 2004, American journal of obstetrics and gynecology.
[31] A. Aktulay,et al. Clinical outcomes of early postplacental insertion of intrauterine contraceptive devices. , 2004, Contraception.
[32] S. Grénman,et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. , 2004, JAMA.
[33] P. Vercellini,et al. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. , 2004, Fertility and sterility.
[34] H. Maia,et al. Insertion of mirena after endometrial resection in patients with adenomyosis. , 2003, The Journal of the American Association of Gynecologic Laparoscopists.
[35] L. Bahamondes,et al. Levonorgestrel‐releasing intrauterine system (Mirena®) as a therapy for endometrial hyperplasia and carcinoma , 2003, Acta obstetricia et gynecologica Scandinavica.
[36] M. Dhont,et al. Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. , 2003, American journal of obstetrics and gynecology.
[37] M. Chen-Mok,et al. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. , 2003, Fertility and sterility.
[38] J. Otero-Flores,et al. A comparative randomized study of three different IUDs in nulliparous Mexican women. , 2003, Contraception.
[39] B. Xiao,et al. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. , 2003, Fertility and sterility.
[40] S. Soysal,et al. A randomized controlled trial of levonorgestrel releasing IUD and thermal balloon ablation in the treatment of menorrhagia. , 2002, Zentralblatt fur Gynakologie.
[41] F. Montz,et al. Intrauterine progesterone treatment of early endometrial cancer. , 2002, American journal of obstetrics and gynecology.
[42] D. Grimes,et al. Noncontraceptive Health Benefits of Intrauterine Devices: A Systematic Review , 2002, Obstetrical & gynecological survey.
[43] L. Bahamondes,et al. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. , 2002, Contraception.
[44] I. Rauramo,et al. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. , 2001, Fertility and sterility.
[45] A. Zeleniuch‐Jacquotte,et al. Role of Exogenous and Endogenous Hormones in Endometrial Cancer , 2001, Annals of the New York Academy of Sciences.
[46] D. Taylor,et al. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. , 2001, The New England journal of medicine.
[47] C. Morrison,et al. Is the intrauterine device appropriate contraception for HIV‐1‐infected women? , 2001 .
[48] I. Sivin,et al. Immediate postabortal contraception with the levonorgestrel intrauterine device, Norplant, and traditional methods. , 2001, Contraception.
[49] R. Raffaelli,et al. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. , 2001, Fertility and sterility.
[50] J. Shelton. Risk of clinical pelvic inflammatory disease attributable to an intrauterine device , 2001, The Lancet.
[51] C. Morrison,et al. Is the intrauterine device appropriate contraception for HIV‐infected women? , 2000, BJOG : an international journal of obstetrics and gynaecology.
[52] F. al-Azzawi,et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial , 2000, The Lancet.
[53] D. Grimes. Intrauterine device and upper-genital-tract infection , 2000, The Lancet.
[54] L. Bahamondes,et al. Acceptability and performance of the levonorgestrel-releasing intrauterine system (Mirena) in Campinas, Brazil. , 2000, Contraception.
[55] R. Luoto,et al. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation‐wide study of 17,360 users , 2000, BJOG : an international journal of obstetrics and gynaecology.
[56] S. Logan,et al. Hormonally impregnated intrauterine systems (IUSs), versus other forms of reversible contraceptives as effective methods of preventing pregnancy. , 2000, The Cochrane database of systematic reviews.
[57] Kuldip Singh,et al. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system. , 1999, Contraception.
[58] K. Schulz,et al. Prophylactic antibiotics for intrauterine device insertion: a metaanalysis of the randomized controlled trials. , 1999, Contraception.
[59] V. Odlind,et al. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. , 1999, Acta obstetricia et gynecologica Scandinavica.
[60] A. Charlett,et al. The rate of diagnosis and demography of pelvic inflammatory disease in general practice: England and Wales , 1999, International journal of STD & AIDS.
[61] A. Kauppila,et al. The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience. , 1999, Fertility and sterility.
[62] I. Cameron,et al. Randomised comparative trial of the intrauterine system and norethisterone levonor gestrel for treatment of idiopathic menorrhagia , 1998 .
[63] I. Milsom,et al. Perforations with intrauterine devices. Report from a Swedish survey. , 1998, Contraception.
[64] H. Koistinen,et al. Levonorgestrel-releasing intrauterine device-wearing women express contraceptive glycodelin A in endometrium during midcycle: another contraceptive mechanism? , 1997, Human reproduction.
[65] S. Suhonen,et al. Three‐year follow‐up of the use of a levonorgestrel‐releasing intrauterine system in hormone replacement therapy , 1997, Acta obstetricia et gynecologica Scandinavica.
[66] J. Forrest. U.S. women's perceptions of and attitudes about the IUD. , 1996, Obstetrical & gynecological survey.
[67] C. Bardin,et al. Mechanisms of action of intrauterine devices. , 1996, Obstetrical & gynecological survey.
[68] J. Suvisaari,et al. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system. , 1996, Contraception.
[69] L. Mattsson,et al. Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women--effects on lipid metabolism during 12 months of treatment. , 1996, International journal of fertility and menopausal studies.
[70] K. Treiman,et al. IUDs--an update. , 1995, Population reports. Series B, Intrauterine devices.
[71] E. Coutinho,et al. Ovarian function after seven years' use of a levonorgestrel IUD , 1995, Advances in contraception : the official journal of the Society for the Advancement of Contraception.
[72] J. Annus,et al. Tubal Infertility: Serologic Relationship to Past Chlamydial and Gonococcal Infection , 1995 .
[73] S. Suhonen,et al. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. , 1995, American journal of obstetrics and gynecology.
[74] E. Searle,et al. Long acting methods of contraception , 1994, BMJ.
[75] T. Bourne,et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial , 1994, The Lancet.
[76] J. Willem,et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer , 1994, The Lancet.
[77] A. Faúndes,et al. Evaluation of the clinical performance of a levonorgestrel-releasing IUD, up to seven years of use, in Campinas, Brazil. , 1993, Contraception.
[78] G. Rybo,et al. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. , 1992, Contraception.
[79] S. Mumford,et al. Was the Dalkon Shield a safe and effective intrauterine device? The conflict between case-control and clinical trial study findings. , 1992, Fertility and sterility.
[80] D. Mishell,et al. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices. , 1992, American journal of obstetrics and gynecology.
[81] T. Farley,et al. Intrauterine devices and pelvic inflammatory disease: an international perspective , 1992, The Lancet.
[82] D. Mishell,et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. , 1991, Contraception.
[83] I. Sivin. Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. , 1991, Obstetrics and gynecology.
[84] I. Milsom,et al. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. , 1991, American journal of obstetrics and gynecology.
[85] V. Odlind,et al. Ovarian function during use of a levonorgestrel-releasing IUD. , 1990, Contraception.
[86] P. Lähteenmäki,et al. The levonorgestrel-releasing intrauterine device. , 1990, Advances in contraceptive delivery systems : CDS.
[87] B. Xiao,et al. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. , 1990, Contraception.
[88] I. Sivin. IUDs are contraceptives, not abortifacients: a comment on research and belief. , 1989, Studies in family planning.
[89] S. Wu,et al. The effect of intrauterine devices, the stainless steel ring, the copper T220, and releasing levonorgestrel, on the bleeding profile and the morphological structure of the human endometrium--a comparative study of three IUDs. A morphometric study of 96 cases. , 1989, Contraception.
[90] J. Annegers,et al. Risk factors for ectopic pregnancy. A population-based study. , 1988 .
[91] N. Nielsen,et al. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study. , 1987, Contraception.
[92] H. Croxatto,et al. Long-term follow-up of women treated with NORPLANTR implants* , 1987 .
[93] E. Cittadini,et al. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. , 1987, Acta Europaea fertilitatis.
[94] D. Mishell,et al. Recovery of fertility after use of the levonorgestrel 20 mcg/d or Copper T 380 Ag intrauterine device. , 1986, Contraception.
[95] T. Luukkainen,et al. Endometrial Morphology During Long‐Term Use of Levonorgestrel‐Releasing Intrauterine Devices , 1986, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[96] P. Lahteenmaki,et al. Sustained intrauterine release of levonorgestrel over five years. , 1986, Fertility and sterility.
[97] T. Luukkainen,et al. TISSUE CONCENTRATIONS OF LEVONORGESTREL IN WOMEN USING A LEVONORGESTREL‐RELEASING IUD , 1982, Clinical endocrinology.
[98] G. Söderberg,et al. Influence of an intrauterine device on the course of an acute salpingitis. , 1981, Contraception.
[99] L Weström,et al. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. , 1980, American journal of obstetrics and gynecology.
[100] T. Luukkainen,et al. Plasma concentrations of levonorgestrel as a function of the release rate of levonorgestrel from medicated intra-uterine devices. , 1980, Acta endocrinologica.
[101] R. Rochat,et al. Intrauterine Device Termination Rates and the Menstrual Cycle Day of Insertion , 1980, Obstetrics and gynecology.
[102] A. Cervantes,et al. [Mechanism of action of intrauterine devices]. , 1979, Ginecologia y obstetricia de Mexico.
[103] J. Paavonen,et al. Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women. , 2007, Contraception.
[104] C. Cwiak,et al. A pilot clinical trial of ultrasound-guided postplacental insertion of a levonorgestrel intrauterine device. , 2007, Contraception.
[105] Germán L. Rosano,et al. Doses of levonorgestrel comparable to that delivered by the levonorgestrel-releasing intrauterine system can modify the in vitro expression of zona binding sites of human spermatozoa. , 2006, Contraception.
[106] A. Lethaby,et al. Surgery versus medical therapy for heavy menstrual bleeding. , 2006, Cochrane Database of Systematic Reviews.
[107] M. Koskenvuo,et al. Pregnancy during the use of levonorgestrel intrauterine system. , 2004, American journal of obstetrics and gynecology.
[108] K. Wellings,et al. Amenorrhea associated with contraception-an international study on acceptability. , 2003, Contraception.
[109] L. Bahamondes,et al. Users’ Perspectives on Bleeding Patterns after Two Years of Levonorgestrel-Releasing Intrauterine System Use , 2002, Drugs in R&D.
[110] Krishnan Sharma,et al. UNITED NATIONS DEPARTMENT OF ECONOMIC AND SOCIAL AFFAIRS , 1999 .
[111] I. Cameron,et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. , 1998, British journal of obstetrics and gynaecology.
[112] T. Raudaskoski,et al. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. , 1995, American journal of obstetrics and gynecology.
[113] V. Odlind,et al. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. , 1994, Contraception.
[114] I. Sivin,et al. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). , 1994, Fertility and sterility.
[115] I. Sivin. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices. , 1991, Obstetrics and gynecology.
[116] H. Croxatto,et al. [Long-term follow-up of women treated with contraceptive implants of levonorgestrel Norplant]. , 1989, Revista chilena de obstetricia y ginecologia.
[117] H. Croxatto,et al. Long-term follow-up of women treated with Norplant implants. , 1987, Contraception.
[118] T. Luukkainen,et al. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. , 1984, Fertility and sterility.
[119] IUD insertion following termination of pregnancy: a clinical trial of the TCu 220C, Lippes loop D, and copper 7. , 1983, Studies in family planning.